RESUMEN
Preclinical researchers confront two overarching agendas related to drug development: selecting interventions amid a vast field of candidates, and producing rigorous evidence of clinical promise for a small number of interventions. We suggest that each challenge is best met by two different, complementary modes of investigation. In the first (exploratory investigation), researchers should aim at generating robust pathophysiological theories of disease. In the second (confirmatory investigation), researchers should aim at demonstrating strong and reproducible treatment effects in relevant animal models. Each mode entails different study designs, confronts different validity threats, and supports different kinds of inferences. Research policies should seek to disentangle the two modes and leverage their complementarity. In particular, policies should discourage the common use of exploratory studies to support confirmatory inferences, promote a greater volume of confirmatory investigation, and customize design and reporting guidelines for each mode.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Proyectos de Investigación/legislación & jurisprudencia , Investigación Biomédica Traslacional/métodos , Animales , Humanos , Guías de Práctica Clínica como Asunto , Investigación Biomédica Traslacional/organización & administraciónRESUMEN
Quantitative trait locus mapping of chemical/inflammatory pain in the mouse identified the Avpr1a gene, which encodes the vasopressin-1A receptor (V1AR), as being responsible for strain-dependent pain sensitivity to formalin and capsaicin. A genetic association study in humans revealed the influence of a single nucleotide polymorphism (rs10877969) in AVPR1A on capsaicin pain levels, but only in male subjects reporting stress at the time of testing. The analgesic efficacy of the vasopressin analog desmopressin revealed a similar interaction between the drug and acute stress, as desmopressin inhibition of capsaicin pain was only observed in nonstressed subjects. Additional experiments in mice confirmed the male-specific interaction of V1AR and stress, leading to the conclusion that vasopressin activates endogenous analgesia mechanisms unless they have already been activated by stress. These findings represent, to the best of our knowledge, the first explicit demonstration of analgesic efficacy depending on the emotional state of the recipient, and illustrate the heuristic power of a bench-to-bedside-to-bench translational strategy.
Asunto(s)
Analgésicos/uso terapéutico , Umbral del Dolor/efectos de los fármacos , Dolor/tratamiento farmacológico , Dolor/genética , Dolor/fisiopatología , Vasopresinas/uso terapéutico , Animales , Animales Recién Nacidos , Capsaicina/efectos adversos , Desamino Arginina Vasopresina/uso terapéutico , Modelos Animales de Enfermedad , Femenino , Estudios de Asociación Genética , Habituación Psicofisiológica/efectos de los fármacos , Habituación Psicofisiológica/genética , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Peso Molecular , Dolor/inducido químicamente , Dimensión del Dolor/efectos de los fármacos , Dimensión del Dolor/métodos , Umbral del Dolor/fisiología , Polimorfismo de Nucleótido Simple/genética , Sitios de Carácter Cuantitativo , Receptores de Vasopresinas/deficiencia , Receptores de Vasopresinas/genética , Factores Sexuales , Estrés Psicológico/genética , Estrés Psicológico/fisiopatologíaRESUMEN
There exists currently a fair degree of introspection in the pain research community about the value of animal research. This review represents a defense of animal research in pain. We discuss the inherent advantage of animal models over human research as well as the crucial complementary roles animal studies play vis-à-vis human imaging and genetic studies. Finally, we discuss recent developments in animal models of pain that should improve the relevance and translatability of findings using laboratory animals. We believe that pain research using animal models is a continuing necessity-to understand fundamental mechanisms, identify new analgesic targets, and inform, guide and follow up human studies-if novel analgesics are to be developed for the treatment of chronic pain.